{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T05:25:09Z","timestamp":1738992309252,"version":"3.37.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guizhou Provincial Basic Research Program","award":["No. Basic of Guizhou Science Cooperation Foundation - ZK [2023] General 337"],"award-info":[{"award-number":["No. Basic of Guizhou Science Cooperation Foundation - ZK [2023] General 337"]}]},{"name":"Southeast Guizhou Basic Research Program","award":["No. Basic of Southeast Guizhou Science Cooperation Foundation [2022] number 18"],"award-info":[{"award-number":["No. Basic of Southeast Guizhou Science Cooperation Foundation [2022] number 18"]}]},{"name":"Guizhou Province high-level innovative talent Training Program","award":["No\uff1aQian thousand layers of talent (2024) 202214"],"award-info":[{"award-number":["No\uff1aQian thousand layers of talent (2024) 202214"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13607-0","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:06:10Z","timestamp":1738944370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PPIH is a novel diagnostic biomarker associated with immune infiltration in cholangiocarcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Jun","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhitao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haini","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"13607_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-pathol-030220-020455","volume":"16","author":"PM Rodrigues","year":"2021","unstructured":"Rodrigues PM, Olaizola P, Paiva NA, et al. Pathogenesis of Cholangiocarcinoma. Annu Rev Pathol. 2021;16:433\u201363.","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"13607_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin J, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"13607_CR3","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejso.2019.04.002","volume":"45","author":"E Alabraba","year":"2019","unstructured":"Alabraba E, Joshi H, Bird N, et al. Increased multimodality treatment options has improved survival for hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. Eur J Surg Oncol. 2019;45(9):1660\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"13607_CR4","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975\u20132018, National Cancer Institute. Bethesda, MD. https:\/\/seer.cancer.gov\/csr\/1975_2018\/, based on November 2020 SEER data submission, posted to the SEER web site, April 2021."},{"issue":"5","key":"13607_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/147323001003800501","volume":"38","author":"J Lee","year":"2010","unstructured":"Lee J, Kim SS. An overview of cyclophilins in human cancers. J Int Med Res. 2010;38(5):1561\u201374.","journal-title":"J Int Med Res"},{"key":"13607_CR6","doi-asserted-by":"publisher","first-page":"609196","DOI":"10.3389\/fimmu.2021.609196","volume":"12","author":"S Gegunde","year":"2021","unstructured":"Gegunde S, Alfonso A, Alvari\u00f1o R, Alonso E, Botana LM. Cyclophilins A, B, and C role in human T lymphocytes upon inflammatory conditions. Front Immunol. 2021;12:609196.","journal-title":"Front Immunol"},{"issue":"2","key":"13607_CR7","first-page":"127","volume":"4","author":"S Teigelkamp","year":"1998","unstructured":"Teigelkamp S, Achsel T, Mundt C, et al. The 20kD protein of human [U4\/U6.U5] tri-snRNPs is a novel cyclophilin that forms a complex with the U4\/U6-specific 60kD and 90kD proteins. RNA. 1998;4(2):127\u201341.","journal-title":"RNA"},{"issue":"21","key":"13607_CR8","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1042\/BCJ20170366","volume":"474","author":"C Rajiv","year":"2017","unstructured":"Rajiv C, Jackson SR, Cocklin S, Eisenmesser EZ, Davis TL. The spliceosomal proteins PPIH and PRPF4 exhibit bi-partite binding. Biochem J. 2017;474(21):3689\u2013704.","journal-title":"Biochem J"},{"issue":"4","key":"13607_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cell.2009.02.009","volume":"136","author":"MC Wahl","year":"2009","unstructured":"Wahl MC, Will CL, L\u00fchrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136(4):701\u201318.","journal-title":"Cell"},{"issue":"3","key":"13607_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/emboj\/21.3.470","volume":"21","author":"DS Horowitz","year":"2002","unstructured":"Horowitz DS, Lee EJ, Mabon SA, Misteli T. A cyclophilin functions in pre-mRNA splicing. EMBO J. 2002;21(3):470\u201380.","journal-title":"EMBO J"},{"key":"13607_CR11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/OTT.S297973","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Zhou W, Wei J, et al. Prognostic Value and Biological functions of RNA binding proteins in stomach adenocarcinoma. Onco Targets Ther. 2021;14:1689\u2013705.","journal-title":"Onco Targets Ther"},{"key":"13607_CR12","doi-asserted-by":"publisher","first-page":"707305","DOI":"10.3389\/fgene.2021.707305","volume":"12","author":"M Li","year":"2021","unstructured":"Li M, Liu Z, Wang J, et al. Systematic analysis identifies a specific RNA-Binding protein-related Gene Model for Prognostication and Risk-Adjustment in HBV-Related Hepatocellular Carcinoma. Front Genet. 2021;12:707305.","journal-title":"Front Genet"},{"issue":"1","key":"13607_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12885-024-12446-9","volume":"24","author":"J Ye","year":"2024","unstructured":"Ye J, Ying J, Chen H, et al. PPIH acts as a potential predictive biomarker for patients with common solid tumors. BMC Cancer. 2024;24(1):681.","journal-title":"BMC Cancer"},{"issue":"20","key":"13607_CR14","first-page":"11448","volume":"15","author":"J Ye","year":"2023","unstructured":"Ye J, Pang Y, Yang X, et al. PPIH gene regulation system and its prognostic significance in hepatocellular carcinoma: a comprehensive analysis. Aging. 2023;15(20):11448\u201370.","journal-title":"Aging"},{"issue":"1","key":"13607_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12935-021-02131-3","volume":"21","author":"Y Pang","year":"2021","unstructured":"Pang Y, Tan G, Yang X, et al. Iron-sulphur cluster biogenesis factor LYRM4 is a novel prognostic biomarker associated with immune infiltrates in hepatocellular carcinoma. Cancer Cell Int. 2021;21(1):463.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"13607_CR16","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/hep.30289","volume":"69","author":"AE Sirica","year":"2019","unstructured":"Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic Cholangiocarcinoma: Continuing challenges and translational advances. Hepatology. 2019;69(4):1803\u201315.","journal-title":"Hepatology"},{"issue":"4","key":"13607_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CEJ.0000000000000468","volume":"28","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Nie SD, Jiang B, Wang J, Lv P. Risk factors for extrahepatic cholangiocarcinoma: a case-control study in China. Eur J Cancer Prev. 2019;28(4):254\u20137.","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"13607_CR18","doi-asserted-by":"publisher","first-page":"e001042","DOI":"10.1136\/esmoopen-2020-001042","volume":"5","author":"AD Ricci","year":"2020","unstructured":"Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora\u2019s box? ESMO Open. 2020;5(5):e001042.","journal-title":"ESMO Open"},{"issue":"3","key":"13607_CR19","doi-asserted-by":"publisher","first-page":"107327482094804","DOI":"10.1177\/1073274820948047","volume":"27","author":"AD Ricci","year":"2020","unstructured":"Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary Tract Cancer: Worthy of a second look. Cancer Control. 2020;27(3):1073274820948047.","journal-title":"Cancer Control"},{"key":"13607_CR20","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.ctarc.2021.100335","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. First-line chemotherapy in advanced biliary Tract Cancer Ten Years after the ABC-02 trial: and yet it moves! Cancer Treat Res Commun. 2021;27:100335.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"13607_CR21","first-page":"467","volume":"9","author":"J Qin","year":"2018","unstructured":"Qin J, Wang M, Qin J, Cai Q, Peng ZH. High promoter activity of cytokeratin-19 gene in cholangiocarcinoma. Mol Clin Oncol. 2018;9(4):467\u201371.","journal-title":"Mol Clin Oncol"},{"issue":"7471","key":"13607_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333\u20139.","journal-title":"Nature"},{"issue":"8","key":"13607_CR23","first-page":"1669","volume":"71","author":"R Macias","year":"2022","unstructured":"Macias R, Cardinale V, Kendall TJ, et al. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut. 2022;71(8):1669\u201383.","journal-title":"Gut"},{"key":"13607_CR24","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.12659\/MSM.895040","volume":"21","author":"B Liang","year":"2015","unstructured":"Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19-9 in patients with Cholangiocarcinoma: a systematic review and Meta-analysis. Med Sci Monit. 2015;21:3555\u201363.","journal-title":"Med Sci Monit"},{"key":"13607_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/bs.pmbts.2018.12.010","volume":"162","author":"P Zeng","year":"2019","unstructured":"Zeng P, Li H, Chen Y, Pei H, Zhang L. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases. Prog Mol Biol Transl Sci. 2019;162:253\u201364.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"4","key":"13607_CR26","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1053\/j.gastro.2020.11.052","volume":"160","author":"JF Fahrmann","year":"2021","unstructured":"Fahrmann JF, Schmidt CM, Mao X, et al. Lead-time trajectory of CA19-9 as an Anchor marker for pancreatic Cancer early detection. Gastroenterology. 2021;160(4):1373\u2013e13836.","journal-title":"Gastroenterology"},{"issue":"3","key":"13607_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/15353702221142614","volume":"248","author":"LM Tan","year":"2023","unstructured":"Tan LM, Ke SP, Li X, et al. The value of serum TRAP1 in diagnosing small cell lung cancer and tumor immunity. Exp Biol Med (Maywood). 2023;248(3):201\u20138.","journal-title":"Exp Biol Med (Maywood)"},{"key":"13607_CR28","doi-asserted-by":"publisher","first-page":"835914","DOI":"10.3389\/fpubh.2022.835914","volume":"10","author":"M Lertpanprom","year":"2022","unstructured":"Lertpanprom M, Silsirivanit A, Tippayawat P, Proungvitaya T, Roytrakul S, Proungvitaya S. High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma. Front Public Health. 2022;10:835914.","journal-title":"Front Public Health"},{"issue":"1","key":"13607_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s40001-023-01575-9","volume":"28","author":"KH Ong","year":"2023","unstructured":"Ong KH, Lai HY, Sun DP, et al. Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma. Eur J Med Res. 2023;28(1):593.","journal-title":"Eur J Med Res"},{"issue":"1","key":"13607_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12967-020-02498-3","volume":"18","author":"J Byrling","year":"2020","unstructured":"Byrling J, Kristl T, Hu D, et al. Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker. J Transl Med. 2020;18(1):343.","journal-title":"J Transl Med"},{"issue":"3\u20134","key":"13607_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","volume":"32","author":"N Beauchemin","year":"2013","unstructured":"Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3\u20134):643\u201371.","journal-title":"Cancer Metastasis Rev"},{"issue":"Suppl 1","key":"13607_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","volume":"73","author":"L Fabris","year":"2021","unstructured":"Fabris L, Sato K, Alpini G, Strazzabosco M. The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology. 2021;73(Suppl 1):75\u201385.","journal-title":"Hepatology"},{"issue":"18","key":"13607_CR33","doi-asserted-by":"publisher","first-page":"e129641","DOI":"10.1172\/jci.insight.129641","volume":"5","author":"S Garaud","year":"2019","unstructured":"Garaud S, Buisseret L, Solinas C, et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 2019;5(18):e129641.","journal-title":"JCI Insight"},{"key":"13607_CR34","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476.","journal-title":"Front Immunol"},{"issue":"6","key":"13607_CR35","first-page":"846","volume":"12","author":"F Vita","year":"2023","unstructured":"Vita F, Olaizola I, Amato F, et al. Heterogeneity Cholangiocarcinoma Immune Biology Cells. 2023;12(6):846.","journal-title":"Heterogeneity Cholangiocarcinoma Immune Biology Cells"},{"issue":"4","key":"13607_CR36","first-page":"597","volume":"3","author":"C Subimerb","year":"2010","unstructured":"Subimerb C, Pinlaor S, Khuntikeo N, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Rep. 2010;3(4):597\u2013605.","journal-title":"Mol Med Rep"},{"issue":"7885","key":"13607_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","volume":"599","author":"B Zhang","year":"2021","unstructured":"Zhang B, Vogelzang A, Miyajima M, et al. B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity. Nature. 2021;599(7885):471\u20136.","journal-title":"Nature"},{"key":"13607_CR38","doi-asserted-by":"publisher","first-page":"647209","DOI":"10.3389\/fimmu.2021.647209","volume":"12","author":"Z Chen","year":"2021","unstructured":"Chen Z, Yu M, Yan J, et al. PNOC expressed by B cells in Cholangiocarcinoma was Survival related and LAIR2 could be a T cell exhaustion biomarker in Tumor Microenvironment: characterization of Immune Microenvironment combining single-cell and bulk sequencing technology. Front Immunol. 2021;12:647209.","journal-title":"Front Immunol"},{"issue":"25","key":"13607_CR39","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui C, Wang J, Fagerberg E, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell. 2021;184(25):6101\u2013e611813.","journal-title":"Cell"},{"issue":"7","key":"13607_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00262-003-0388-5","volume":"52","author":"AC Diederichsen","year":"2003","unstructured":"Diederichsen AC, Jv H, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+\/CD8\u2009+\u2009ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 2003;52(7):423\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"13607_CR41","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1016\/j.eclinm.2021.101134","volume":"41","author":"F Li","year":"2021","unstructured":"Li F, Li C, Cai X, et al. The association between CD8\u2009+\u2009tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine. 2021;41:101134.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"13607_CR42","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","volume":"164","author":"AK Palucka","year":"2016","unstructured":"Palucka AK, Coussens LM. The basis of Oncoimmunology. Cell. 2016;164(6):1233\u201347.","journal-title":"Cell"},{"issue":"3\u20134","key":"13607_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","volume":"26","author":"JE Talmadge","year":"2007","unstructured":"Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007;26(3\u20134):373\u2013400.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"13607_CR44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12967-022-03342-6","volume":"20","author":"H Yang","year":"2022","unstructured":"Yang H, Yan M, Li W, Xu L, SIRP\u03b1. PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma. J Transl Med. 2022;20(1):140.","journal-title":"J Transl Med"},{"issue":"2","key":"13607_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tranon.2018.10.007","volume":"12","author":"K Vaeteewoottacharn","year":"2019","unstructured":"Vaeteewoottacharn K, Kariya R, Pothipan P, et al. Attenuation of CD47-SIRP\u03b1 Signal in Cholangiocarcinoma Potentiates Tumor-Associated macrophage-mediated phagocytosis and suppresses intrahepatic metastasis. Transl Oncol. 2019;12(2):217\u201325.","journal-title":"Transl Oncol"},{"issue":"4","key":"13607_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jhepr.2019.06.003","volume":"1","author":"E Loeuillard","year":"2019","unstructured":"Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 2019;1(4):297\u2013311.","journal-title":"JHEP Rep"},{"issue":"2","key":"13607_CR47","doi-asserted-by":"publisher","first-page":"106003","DOI":"10.1016\/j.isci.2023.106003","volume":"26","author":"Y Shen","year":"2023","unstructured":"Shen Y, Xu S, Ye C, et al. Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma. iScience. 2023;26(2):106003.","journal-title":"iScience"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13607-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:06:21Z","timestamp":1738944381000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13607-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13607"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13607-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of the Ethics Committee of the Second Affiliated Hospital of Guizhou Medical University. Written informed consent was obtained from individual or guardian participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}